Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: Rescue by guanylyl-cyclase activation

Diabetes

Volumn 59, Issue 8, 2010, Pages 2001-2009

  Schäfer, Andreas ^a   Galuppo, Paolo ^a   Fraccarollo, Daniela ^a   Vogt, Christian ^a   Widder, Julian D ^a   Pfrang, Julia ^a   Tas, Piet ^a   Barbosa Sicard, Eduardo ^b   Ruetten, Hartmut ^c   Ertl, Georg ^a   Fleming, Ingrid ^b   Bauersachs, Johann ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N,N DIETHYLAMINO)DIAZENOLATE 2 OXIDE; 20 HYDROXYICOSATETRAENOIC ACID; ACETYLCHOLINE; ANTHRANILIC ACID DERIVATIVE; ATACIGUAT; CYTOCHROME P450 2E1; GUANYLATE CYCLASE; HMR 1766; HYDROXYICOSATETRAENOIC ACID; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENZYME ACTIVATION; ENZYME INDUCTION; FATTY ACID SYNTHESIS; ICOSANOID METABOLISM; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE CONTRACTILITY; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE; VASOMOTOR REFLEX;

ANIMALS; ANTHRANILIC ACIDS; AORTA, THORACIC; CYTOCHROME P-450 CYP2E1; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANYLATE CYCLASE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; SULFONAMIDES; SUPEROXIDES; UP-REGULATION; VASODILATION;

EID: 77955342561     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1668     Document Type: Article

References (44)

1. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008;6:52-60
2. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999;31:5-14
3. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2. Altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001;27:436-447
4. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561 (Pubitemid 44330154)
5. Etienne P, Parés-Herbuté N, Mani-Ponset L, Gabrion J, Rabesandratana H, Herbuté S, Monnier L. Phenotype modulation in primary cultures of aortic smooth muscle cells from streptozotocin-diabetic rats. Differentiation 1998;63:225-236 (Pubitemid 28428736)
6. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, Felaco M. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation. J Cell Physiol 2003;196:378-385 (Pubitemid 36775886)
7. Faries PL, Rohan DI, Takahara H, Wyers MC, Contreras MA, Quist WC, King GL, LoGerfo FW. Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J Vasc Surg 2001;33:601-607 (Pubitemid 32215612)
8. Fukumoto S, Koyama H, Hosoi M, Yamakawa K, Tanaka S, Morii H, Nishizawa Y. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 1999;85:985-991
9. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 1995;96:141-149
10. Chiche J-D, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD, Filippov G, Janssens SP, Rosenzweig A, Bloch KD. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 1998;273:34263-34271 (Pubitemid 129758369)
11. Dupuis M, Soubrier F, Brocheriou I, Raoux S, Haloui M, Louedec L, Michel JB, Nadaud S. Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation 2004;110:867-873 (Pubitemid 39096016)
12. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-291 (Pubitemid 37048240)
13. Osinski MT, Rauch BH, Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 2001;59:1044-1050 (Pubitemid 32381583)
14. Young DV, Serebryanik D, Janero DR, Tam SW. Suppression of proliferation of human coronary artery smooth muscle cells by the nitric oxide donor, S-nitrosoglutathione, is cGMP-independent. Mol Cell Biol Res Comm 2000;4:32-36 (Pubitemid 32060001)
15. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 1997;120:681-689 (Pubitemid 27089418)
16. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, Schafer AI. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 2002;291:1014-1021 (Pubitemid 34694377)
17. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C, Muelsch A. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006;69:1260-1268
18. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, Roussos C, Papapetropoulos A. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:H1763-H1771
19. Schäfer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J. Soluble guanylyl cyclase activation with HMR 1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 2006;26:2813-2818
20. Schäfer A, Bauersachs J. Therapeutic targets of ataciguat. Drugs Future 2007;32:731-738
21. 2+-independent activation of the endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999;96:1123-1128
22. Schäfer A, Fraccarollo D, Hildemann S, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect of endothelial function. Cardiovasc Res 2003;58:655-662 (Pubitemid 36694451)
23. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007;49:717-727 (Pubitemid 351688335)
24. Fink B, Laude K, McCann L, Doughan A, Harrison DG, Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol 2004;287:C895-C902 (Pubitemid 39238312)
25. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002;105:1656-1662 (Pubitemid 34298608)
26. Sun H, Zhong M, Miao Y, Ma X, Gong HP, Tan HW, Zhang Y, Zhang W. Impaired elastic properties of the aorta in fat-fed, streptozotocin-treated rats. Vascular remodeling in diabetic arteries. Cardiology 2009;114:107-113
27. Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, Frye RF, Zemaitis MA. The effect of isoniazid on CY. Drug Metab Dispos 2004;32: 727-733
28. Alonso-Galicia M, Maier KG, Greene AS, Cowley AW Jr, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol 2002;283:R60-R68 (Pubitemid 34863911)
29. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185
30. Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 2003;41:801-806 (Pubitemid 36314594)
31. Munzel T, Genth-Zotz S, Hink U. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension 2007;49:974-976
32. Fraccarollo D, Widder J, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J. Improvement of left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008;118:818-827
33. Kobayashi T, Kamata K. Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes. Br J Pharmacol 1999;127:835-842 (Pubitemid 29295341)
34. Fulton DJ, Hodgson WC, Sikorski BW, King RG. Attenuated responses to endothelin-1, KCl and CaCl2, but not noradrenaline, of aortae from rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 1991;104: 928-932
35. Nuno DW, Harrod JS, Lamping KG. Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009;297:H1469-H1477
36. Xie Z, Su W, Guo Z, Pang H, Post SR, Gong MC. Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc Res 2006;69:491-501 (Pubitemid 43098805)
37. Okon EB, Szado T, Laher I, McManus B, van Breemen C. Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003;40:520-530 (Pubitemid 38186462)
38. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003;55:77-85
39. Raza H, Prabu SK, Robin MA, Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: tissue-specific variations and roles in oxidative stress. Diabetes 2004;53:185-194
40. Zhang F, Deng H, Kemp R, Singh H, Gopal VR, Falck JR, Laniado-Schwartzman M, Nasjletti A. Decreased levels of cytochrome P450 2E1-derived eicosanoids sensitize renal arteries to constrictor agonists in spontaneously hypertensive rats. Hypertension 2005;45:103-108
41. Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, Frye RF, Zemaitis MA. The effect of isoniazid on CY. Drug Metab Dispos 2004;32: 727-733
42. Gergel D, Misik V, Riesz P, Cederbaum AI. Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch Biochem Biophys 1997;337:239-250
43. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002;35:263-273
44. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture Cyp2e1. Drug Metab Dispos 2007;35:1-8